S Gail Eckhardt, MD

Associate Dean of Cancer Programs; Director of the LIVESTRONG Cancer Institute; Department Chair; Professor

1991 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1991 2019

Filter
Review article
2017
137 Citations (Scopus)

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G., Gonzalez-Suarez, E., Hermans, E., Hidalgo, M., Jarzabek, M. A., De Jong, S. & 22 others, Jonkers, J., Kemper, K., Lanfrancone, L., Mælandsmo, G. M., Marangoni, E., Marine, J. C., Medico, E., Norum, J. H., Palmer, H. G., Peeper, D. S., Pelicci, P. G., Piris-Gimenez, A., Roman-Roman, S., Rueda, O. M., Seoane, J., Serra, V., Soucek, L., Vanhecke, D., Villanueva, A., Vinolo, E., Bertotti, A. & Trusolino, L., Apr 1 2017, In : Nature Reviews Cancer. 17, 4, p. 254-268 15 p.

Research output: Contribution to journalReview article

Precision Medicine
Heterografts
Neoplasms
Internationality
Therapeutics
2016
31 Citations (Scopus)

The changing landscape of phase I trials in oncology

Wong, K. M., Capasso, A. & Eckhardt, S. G., Feb 1 2016, In : Nature Reviews Clinical Oncology. 13, 2, p. 106-117 12 p.

Research output: Contribution to journalReview article

Biomarkers
Pharmaceutical Preparations
Neoplasms
Cytotoxins
Combination Drug Therapy
2015
Drug Dose Response Relationship
Medical Oncology
Antineoplastic Agents
Patient Selection
Research Design
2014

Potential role of MEK inhibition in treating patients with colorectal cancer

Brittain, P., Eckhardt, S. G. & Lieu, C. H., Jan 1 2014, In : Current Cancer Therapy Reviews. 10, 1, p. 34-38 5 p.

Research output: Contribution to journalReview article

Mitogen-Activated Protein Kinase Kinases
Colorectal Neoplasms
Mitogen-Activated Protein Kinases
Neoplasms
Biomarkers
52 Citations (Scopus)

Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors

Pitts, T. M., Davis, S. L., Eckhardt, S. G. & Bradshaw-Pierce, E. L., Jan 1 2014, In : Pharmacology and Therapeutics. 142, 2, p. 258-269 12 p.

Research output: Contribution to journalReview article

Cell Cycle
Phosphotransferases
Mitosis
Protein Kinases
Neoplasms
21 Citations (Scopus)

Triple-negative breast cancer: Bridging the gap from cancer genomics to predictive biomarkers

Davis, S. L., Eckhardt, S. G., Tentler, J. J. & Diamond, J. R., Jan 1 2014, In : Therapeutic Advances in Medical Oncology. 6, 3, p. 88-100 13 p.

Research output: Contribution to journalReview article

Triple Negative Breast Neoplasms
Genomics
Biomarkers
Neoplasms
Therapeutics
2013
23 Citations (Scopus)

From bench to bedside: Lessons learned in translating preclinical studies in cancer drug development

Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R. & Eckhardt, S. G., Oct 2 2013, In : Journal of the National Cancer Institute. 105, 19, p. 1441-1456 16 p.

Research output: Contribution to journalReview article

Pharmaceutical Preparations
Neoplasms
Drug Combinations
Patient Selection
Therapeutics
2012
18 Citations (Scopus)

JAK2 inhibition for the treatment of hematologic and solid malignancies

Harry, B. L., Eckhardt, S. G. & Jimeno, A., May 1 2012, In : Expert Opinion on Investigational Drugs. 21, 5, p. 637-655 19 p.

Research output: Contribution to journalReview article

Janus Kinase 2
Hematologic Neoplasms
Mutation
Neoplasms
Philadelphia Chromosome
563 Citations (Scopus)

Patient-derived tumour xenografts as models for oncology drug development

Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A. & Eckhardt, S. G., Jun 1 2012, In : Nature Reviews Clinical Oncology. 9, 6, p. 338-350 13 p.

Research output: Contribution to journalReview article

Heterografts
Pharmaceutical Preparations
Neoplasms
Inbred NOD Mouse
SCID Mice
2010

Management strategies for patients with KRAS mutations

Leong, S., Eckhardt, S. G. & Messersmith, W. A., Oct 1 2010, In : Current Colorectal Cancer Reports. 6, 4, p. 199-205 7 p.

Research output: Contribution to journalReview article

Mutation
Epidermal Growth Factor Receptor
Colorectal Neoplasms
Precision Medicine
Antibodies
8 Citations (Scopus)

Novel agents in the treatment of metastatic colorectal cancer

Leong, S., Messersmith, W. A., Tan, A. C. & Eckhardt, S. G., May 1 2010, In : Cancer Journal. 16, 3, p. 273-282 10 p.

Research output: Contribution to journalReview article

Colorectal Neoplasms
Therapeutics
Clinical Trials
Explosions
Research
2009
3 Citations (Scopus)

BRCA in breast cancer: From risk assessment to therapeutic prediction

Diamond, J. R., Borges, V. F., Eckhardt, S. G. & Jimeno, A., Dec 1 2009, In : Drug News and Perspectives. 22, 10, p. 603-608 6 p.

Research output: Contribution to journalReview article

Breast Neoplasms
Mutation
Double-Stranded DNA Breaks
Germ-Line Mutation
Therapeutics
424 Citations (Scopus)

Clinical applications of metabolomics in oncology: A review

Spratlin, J. L., Serkova, N. J. & Eckhardt, S. G., Jan 15 2009, In : Clinical Cancer Research. 15, 2, p. 431-440 10 p.

Research output: Contribution to journalReview article

Metabolomics
Early Detection of Cancer
Molecular Imaging
Translational Medical Research
Systems Biology
174 Citations (Scopus)

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection

Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A. & Eckhardt, S. G., Mar 1 2009, In : Journal of Clinical Oncology. 27, 7, p. 1130-1136 7 p.

Research output: Contribution to journalReview article

Epidermal Growth Factor Receptor
Patient Selection
Colorectal Neoplasms
Mutation
Pharmaceutical Preparations
21 Citations (Scopus)

KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer

Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A. & Eckhardt, S. G., Mar 1 2009, In : Cancer Journal. 15, 2, p. 110-113 4 p.

Research output: Contribution to journalReview article

Colorectal Neoplasms
Mutation
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Biomarkers

The importance of KRAS status in managing metastatic colorectal cancer

Leong, S., Eckhardt, S. G., Jimeno, A. & Messersmith, W., Jul 1 2009, In : Current Colorectal Cancer Reports. 5, 3, p. 129-134 6 p.

Research output: Contribution to journalReview article

Colorectal Neoplasms
Standard of Care
Epidermal Growth Factor Receptor
Colonic Neoplasms
Survival Rate
2008

Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ?

Nallapareddy, S., Eckhardt, S. G. & Messersmith, W., Jul 1 2008, In : Current Colorectal Cancer Reports. 4, 3, p. 167-172 6 p.

Research output: Contribution to journalReview article

irinotecan
oxaliplatin
Colonic Neoplasms
Drug Therapy
Therapeutics
320 Citations (Scopus)
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Neoplasms
TNF-Related Apoptosis-Inducing Ligand Receptors
124 Citations (Scopus)

Targeted manipulation of apoptosis in cancer treatment

Call, J. A., Eckhardt, S. G. & Camidge, D. R., Oct 1 2008, In : The Lancet Oncology. 9, 10, p. 1002-1011 10 p.

Research output: Contribution to journalReview article

Apoptosis
Neoplasms
Therapeutics
Pharmaceutical Preparations
Cell Death
2007

Combination of anti-EGFR drugs with anti-angiogenic or other signal transduction inhibitors as a rational approach to cancer therapy

Morelli, M. P., Spratlin, J. & Eckhardt, S. G., Nov 1 2007, In : Current Cancer Therapy Reviews. 3, 4, p. 284-291 8 p.

Research output: Contribution to journalReview article

Angiogenesis Inhibitors
Epidermal Growth Factor Receptor
Signal Transduction
Neoplasms
Therapeutics
84 Citations (Scopus)

NMR-based metabolomics: Translational application and treatment of cancer

Serkova, N. J., Spratlin, J. L. & Eckhardt, S. G., Dec 1 2007, In : Current Opinion in Molecular Therapeutics. 9, 6, p. 572-585 14 p.

Research output: Contribution to journalReview article

Metabolomics
Metabolome
Neoplasms
Cytostatic Agents
Body Fluids
22 Citations (Scopus)

Priorities in colorectal cancer research: Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups

O'Dwyer, P. J., Eckhardt, S. G., Haller, D. G., Tepper, J., Ahnen, D., Hamilton, S., Benson, A. B., Rothenberg, M., Petrelli, N., Lenz, H. J., Diasio, R., DuBois, R., Sargent, D., Sloan, J., Johnson, C. D., Comis, R. L. & O'Connell, M. J., Jun 1 2007, In : Journal of Clinical Oncology. 25, 16, p. 2313-2321 9 p.

Research output: Contribution to journalReview article

Colorectal Neoplasms
Clinical Trials
Patient Advocacy
Aptitude
Drug Industry
660 Citations (Scopus)

Sunitinib: From rational design to clinical efficacy

Chow, L. Q. M. & Eckhardt, S. G., Mar 1 2007, In : Journal of Clinical Oncology. 25, 7, p. 884-896 13 p.

Research output: Contribution to journalReview article

Neoplasms
Protein-Tyrosine Kinases
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Receptor Protein-Tyrosine Kinases
2001
677 Citations (Scopus)

Development of matrix metalloproteinase inhibitors in cancer therapy

Hidalgo, M. & Eckhardt, S. G., Feb 7 2001, In : Journal of the National Cancer Institute. 93, 3, p. 178-193 16 p.

Research output: Contribution to journalReview article

Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Peptidomimetics
Tetracyclines
Neoplasms
1999
12 Citations (Scopus)

Angiogenesis inhibitors as cancer therapy

Eckhardt, S. G., Jan 15 1999, In : Hospital Practice. 34, 1

Research output: Contribution to journalReview article

Angiogenesis Inhibitors
Neoplasms
Cytostatic Agents
Cell Death
Therapeutics
1997
2 Citations (Scopus)

New anticancer agents.

Weiss, G. R., Burris, H. A., Eckhardt, S. G., Rodriguez, G. I., Sharma, S. & Valley, A., Jan 1 1997, In : Cancer chemotherapy and biological response modifiers. 17, p. 178-194 17 p.

Research output: Contribution to journalReview article

Pathologic Neovascularization
Suramin
Thymidylate Synthase
Triazines
Dacarbazine
1996
1 Citation (Scopus)

New anticancer agents.

Weiss, G. R., Burris, H. A., Eckardt, J. R., Eckhardt, S. G., Fields, S. M., O'Rourke, T., Rodriguez, G. I., Rothenberg, M. L. & Valley, A. J., Jan 1 1996, In : Cancer chemotherapy and biological response modifiers. 16, p. 132-167 36 p.

Research output: Contribution to journalReview article

Alkylating Antineoplastic Agents
Pathologic Neovascularization
Investigational Drugs
Platinum Compounds
Intercalating Agents
1995
3 Citations (Scopus)

New anticancer agents in clinical development

Eckardt, J., Eckhardt, S. G., Villalona-Calero, M., Drengler, R. & Von Hoff, D., Dec 1 1995, In : ONCOLOGY. 9, 12, p. 1321-1331 11 p.

Research output: Contribution to journalReview article

irinotecan
9-aminocamptothecin
docetaxel
gemcitabine
Topoisomerase I Inhibitors
12 Citations (Scopus)

New anticancer agents in clinical development

Eckardt, J., Eckhardt, S. G., Villalona-Calero, M., Drengler, R. & Von Hoff, D., Dec 18 1995, In : ONCOLOGY. 9, 11, p. 1191-1199 9 p.

Research output: Contribution to journalReview article

irinotecan
9-aminocamptothecin
docetaxel
gemcitabine
Antineoplastic Agents